Organisation paid for research Program year 2025 Source: CMS Open Payments

Calin Arimie MD

Neither a doctor nor a teaching hospital

Research payments

$1,039,833

47 payments

Through program year 2025, Calin Arimie MD is reported as receiving $1,039,833 in research payments, across 47 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $171,186 8
2024 Research $234,831 8
2023 Research $305,910 8
2022 Research $129,344 9
2021 Research $80,104 6
2020 Research $89,922 7
2019 Research $28,536 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,039,833 47 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $287,146 5 payments
  2. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $244,485 2 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $182,322 7 payments
  4. A Phase 3, Multicenter, Open Label, Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease $128,351 8 payments
  5. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 1) $47,915 4 payments
  6. A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $45,319 7 payments
  7. A Phase 3 Multicenter Randomized Double-Blind Placebo- and Active- Controlled Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease $24,192 2 payments
  8. A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (Lucent 2) $23,221 3 payments
  9. A Phase 3 Multicenter Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis Lucent 3 $19,254 2 payments
  10. A Phase 3 Multicenter Open Label Long Term Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Crohns Disease $17,979 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record